At what time do you switch to olaparib after FOLFIRINOX in BRCA mutated metastatic pancreatic adenocarcinoma patients?

Based on POLO - an individual with germline BRCA+ PDAC had to have at least 16 weeks of platinum based therapy (majority had (m)FOLFIRINOX, small # cisplatin/gemcitabine) - before randomization to olaparib or placebo (Golan et alm NEJM, 2019). So, based on the data - this option is there to consider...

Based on POLO trial after you have given 6 months of FOLFIRINOX if they do not have progressive disease you can start on Olaparib.

2nd line